Synonyms: PRO 140 | PRO-140 | PRO140 | Vyrologix®
Compound class:
Antibody
Comment: Leronlimab (PRO140) is a humanized anti-CCR5 (C-C motif chemokine receptor 5) monoclonal antibody [5-6]. It was originally developed by CytoDyn as a novel strategy to manage CCR5-tropic HIV infection [4].
SARS-CoV-2 and COVID-19: Leronlimab has been administered to a number of patients with severe COVID-19, to determine its potential to reduce cytokine storm caused by this disease. |
Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
10751 | leronlimab |
Synonyms ![]() |
PRO 140 | PRO-140 | PRO140 | Vyrologix® |
Database Links ![]() |
|
Specialist databases | |
GPCRdb Ligand | leronlimab |
IMGT/mAb-DB | 807 |
Other databases | |
GtoPdb PubChem SID | 405560193 |
Search PubMed clinical trials | leronlimab |
Search PubMed titles | leronlimab |
Search PubMed titles/abstracts | leronlimab |